Introduction
Endometriosis affects at least 10% of reproductive age women and is characterized by the presence of ectopic endometrium. The association between endometriosis and infertility is well established, but the mechanisms responsible are unknown (Olive and Schwartz, 1993) . Multiple factors have been implicated including distortion of the pelvic anatomy, abnormalities of hormone secretion (Ayers et al., 1987) , alterations in peritoneal fluid (Halme et al., 1987) , disorders of fertilization (Mills et al., 1992) , and immunoregulatory dysfunction (Witz et al., 1994) . Alterations in endometrial development in patients with endometriosis may contribute to endometriosis related infertility. Reports from several in-vitro fertilization (IVF)/ embryo transfer programmes indicate patients with endometriosis have decreased implantation rates (Hahn et al., 1986; Simón et al., 1994; Arici et al., 1996) . A surgically-induced mouse model of endometriosis also demonstrates failure of implantation as a mechanism of endometriosis associated infertility (Hahn et al., 1986) . Although histologically normal, examination of eutopic endometrium from women with endometriosis has revealed other defects. Ultrastructural defects have been reported in the endometrium of women with endometriosis (Fedele et al., 1990) . Molecular markers of endometrial receptivity are altered in patients with endometriosis; integrin expression patterns are aberrant in the native endometrium of women with endometriosis (Lessey et al., 1995 (Lessey et al., , 1997 Hii and Rogers, 1998) . Other alterations of biochemical or molecular markers have been noted including metalloproteinases (Osteen et al., 1996; Sharpe Timms, 1997) , soluble urokinase-type plasminogen activator (suPA-R) (Sillem et al., 1997) , oestrogen receptor (ER) splice variants (Fujimoto et al., 1997) , vascular endothelial growth factor (VEGF) (Shifren et al., 1996) , complement (C3) (Bartosik et al., 1987; Isaacson et al., 1990) , aromatase (Noble et al., 1996) , CA-125 (McBean and Brunstead, 1993) , heat shock protein and interleukin 6 (IL6) (Tseng et al., 1996) . HOXA10 and HOXA11 are homeobox genes that mediate embryonic development (Krumlauf, 1992; McGinnis and Krumlauf, 1992) including the development of the reproductive tract (Favier and Dolle, 1997; Taylor et al., 1997) . They are translated into transcription factors that regulate a battery of downstream genes necessary for growth and differentiation. We have recently demonstrated that HOX genes play an analogous role in endometrial development during the adult menstrual cycle (Taylor et al., 1998 (Taylor et al., , 1999 . HOX gene expression possibly regulates the growth and development of the human endometrium (Taylor et al., 1997) . HOXA10 and HOXA11 gene expression varies in response to sex steroids during the menstrual cycle, with dramatic up-regulation in the mid-secretory phase, the time of implantation.
Expression of each of these Hox genes is necessary for implantation in the mouse. Mice with a targeted mutation of either of these genes have uterine factor infertility, producing normal embryos, but with a uterus which lacks the ability of wild-type embryos to implant (Hsieh-Li et al., 1995; Satokata et al., 1995; Favier and Dolle, 1997) . We have recently shown that HOXA10 and HOXA11 likely play a similar role in human implantation (Taylor et al., 1997 (Taylor et al., , 1998 (Taylor et al., , 1999 . HOXA10 and HOXA11 are expressed in the adult human endometrial stroma and glands and are differentially expressed in the developing endometrium during the menstrual cycle. HOX genes may affect endometrial development in a way analogous to their role in embryonic development, leading to endometrial growth, differentiation and receptivity. In women HOXA10 and HOXA11 are up-regulated in the mid-secretory endometrium, at the time of implantation. The extraordinarily high conservation of HOX gene function and the spatial and temporal Expression was seen in the first and second half of the proliferative phase (P1 and P2 respectively) of the menstrual cycle after hybridization to a probe specific to the HOXA10 or G3PD genes. Representative samples showed a lack of significant upregulation between the proliferative phase (P1 and P2) and the midand late secretory phase (S2 and S3). Endometriosis patients showed altered HOXA10 expression. There was no statistically significant change in HOXA10 expression throughout the menstrual cycle. *Indicates a significant difference between controls and endometriosis patients (P Ͻ 0.01). P ϭ proliferative phase; S1 ϭ early secretory phase; S2 ϭ midsecretory phase; S3 ϭ late secretory phase of the menstrual cycle. expression pattern of HOXA10 and HOXA11 in the endometrium suggest that these HOX genes play an essential role in human implantation. In this study we determined the levels of expression of HOXA10 and HOXA11 in the eutopic endometrium of patients with endometriosis. Alterations of the HOXA10 and HOXA11 genes, whose expression is necessary for implantation, may provide evidence of molecular alterations in the endometrium of these patients, and would suggest a defect in the development and receptivity of the endometrium in patients with endometriosis.
Materials and methods

Tissue collection
Endometrium was collected from 40 normal cycling women or from an equal number of women with histologically proven endometriosis, Figure 3 . HOXA11 expression was also altered in the endometrium of patients with endometriosis. Controls showed the expected increase in HOXA11 at the time of implantation. Patients with endometriosis lacked the increased amounts of HOXA11 mRNA in the mid-and late stages of the secretory phase. P ϭ proliferative phase; S1 ϭ early secretory phase; S2 ϭ mid-secretory phase; S3 ϭ late secretory phase of the menstrual cycle. *Indicates a significant difference between controls and endometriosis patients (P Ͻ 0.01).
by endometrial biopsy under an approved institutional Human Investigations Committee protocol. Half of the tissue was immediately frozen in the liquid nitrogen and stored at -72°C. The other half of the tissue sample was fixed in formalin, embedded in paraffin, sectioned and stained with haematoxylin and eosin. Menstrual cycle dating was determined by menstrual history and confirmed by histological examination using the criteria of Noyes et al. (1950) . Patients receiving hormonal therapy or currently undergoing evaluation of infertility were excluded.
Northern blot analysis
Tissues were individually homogenized in 4 M guanidinium thiocyanate, 25 mM sodium citrate (pH 7.0), 0.5% sarkosyl, and 0.1 M 2-mercaptoethanol. Total RNA was size-fractioned on a 1% agarose-0.66 M formaldehyde gel and sequentially hybridized with a 32 Plabelled riboprobe as described below. Hybridization was performed overnight at 60°C in 50% formamide, 1ϫ sodium chloride/sodium citrate (SSC), 5ϫ Denhardt's reagent, 0.2% tRNA, and 32 P-labelled riboprobe at 2ϫ10 6 cpm/ml. The filter was washed twice at 86°C for 30 min in 0.1ϫ SSC and 0.1% SDS. Kodak (Rochester, NY, USA) X-Omat AR film was exposed overnight at -70°C.
Probe preparation
Plasmids used for probe preparation were a generous gift from E.Boncinnelli. pGEM plasmids containing sequence from the 3Ј untranslated region of either human HOXA10 or HOXA11 were linearized with EcoRI or HindIII (New England Biolabs, Beverly, MA, USA), ethanol precipitated and used as a template for generation of riboprobes. Radiolabelled RNA probes were generated by in-vitro transcription using the Promega Riboprobe Kit (Promega, Madison, WI, USA). Antisense probes were generated using the appropriate RNA polymerase (T7 or SP6) and labelled with α-[ 32 P]-UTP (Amersham, Arlington Heights, IL, USA).
Statistical analysis
The autoradiographic bands were quantified using a laser densitometer (Molecular Dynamics Inc, Sunnyvale, CA, USA same lane hybridized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Data were analysed using analysis of variance. P Ͻ 0.05 was considered to be statistically significant.
Results
Endometrium from 40 control patients was analysed for HOXA10 and HOXA11 expression by Northern blot analysis. In all patients, the expected up-regulation of HOXA10 and HOXA11 expression in the mid-luteal phase was observed, as we have previously demonstrated (Taylor et al., 1998 (Taylor et al., , 1999 .
Endometria from 40 patients with endometriosis were analysed in the same fashion. The eutopic endometria obtained from patients with endometriosis failed to show the equivalent up-regulation of either the HOXA10 or HOXA11 genes at the time of implantation. Representative samples are shown in Figure 1 . Densitometry was performed on the Northern blot analysis of all samples normalized to GAPDH, and summarized in Figure 2 . Levels of HOXA10 expression were similar in the proliferative and early secretory phases and not statistically different. In both the mid-and late segments of the secretory phase, a statistically significant difference was noted in endometrial HOXA10 expression between patients with or without endometriosis (P Ͻ 0.01). A similar difference was noted with HOXA11 ( Figure 3 ). This failure to increase HOX gene mRNA levels did not depend on the stage of the disease and occurred despite in-phase endometrial histology.
Discussion
The pathogenesis of endometriosis associated infertility is unclear. These data suggest a defect in regulation of HOX gene expression in the endometrium of patients with endometriosis. Expression of each of these genes is necessary for implantation. Failure of the normal increase in HOXA10 and HOXA11 mRNA levels to occur at the beginning of the window of implantation, may be one mechanism responsible for endometriosis related infertility. Whether this defect is inherent to the eutopic endometrium or the result of other factors associated with endometriosis remains to be demonstrated. These data suggest that a defect in endometrial development exists in patients with endometriosis, and that failure of implantation may contribute to their infertility.
Alterations in other molecules expressed in the endometria have been reported in endometriosis (Isaacson et al., 1990; Lessey et al., 1994; Noble et al., 1996; Shifren et al., 1996; Fujimoto et al., 1997; Sharpe Timms, 1997; Sillem et al., 1997) . In the absence of histological alteration, molecular defects in the endometrium may be responsible for failure of implantation. In mice with a targeted disruption of either the Hoxa10 or Hoxa11 gene, implantation cannot occur despite a histologically normal endometrium (Hsieh-Li, et al., 1995; Satokata et al., 1995) . Similarly a defect in HOX expression in patients with endometriosis may lead to a decrease in implantation without an appreciable pathology noted on histological examination. Very few molecules are known to affect implantation specifically when a targeted mutation is produced in mice; it is interesting to note that these defects are often 1330 undetectable on histological examination. Molecular markers may be a more valuable way to assess the receptivity of the endometrium.
Hox genes function as transcription factors and are early regulators of tissue identity in embryonic development (Krumlauf, 1992; McGinnis and Krumlauf, 1992) . It is likely they function in an analogous role in cyclic endometrial development (Taylor et al., 1998 (Taylor et al., , 1999 . Other molecular markers of implantation or of endometrial development are likely downstream target genes of Hox genes -either direct or indirect. It will be interesting to determine if any of the structural molecules or growth factors that are involved in implantation are regulated by HOXA10 or HOXA11. Alterations in HOX genes can be expected to produce a cascade of other defects in the expression of downstream target genes. Hox genes may be important early initiators of signal transduction that lead to the proper molecular development of the endometrium and to endometrial receptivity. It is likely many of the molecular, ultrastructural and clinical alterations seen in patients with endometriosis are mediated through alterations in HOX gene expression.
